|1.||Thompson, Kimberly M: 17 articles (01/2015 - 12/2006)|
|2.||Centers for Disease Control and Prevention (CDC): 16 articles (06/2015 - 01/2001)|
|3.||Sutter, Roland W: 15 articles (12/2015 - 10/2004)|
|4.||Pallansch, Mark A: 14 articles (11/2015 - 10/2004)|
|5.||Duintjer Tebbens, Radboud J: 13 articles (01/2015 - 01/2008)|
|6.||Aylward, R Bruce: 7 articles (12/2015 - 01/2004)|
|7.||Kew, Olen M: 7 articles (06/2015 - 10/2004)|
|8.||Cochi, Stephen L: 7 articles (01/2015 - 01/2004)|
|9.||Burns, Cara C: 6 articles (06/2015 - 06/2011)|
|10.||Grassly, Nicholas C: 6 articles (10/2014 - 10/2008)|
04/12/2007 - "After poliomyelitis has been eradicated, access to live polioviruses will be highly restricted and the use of oral poliovirus vaccine (OPV) will probably be discontinued. "
10/01/2011 - "The Global Polio Eradication Initiative (GPEI) currently based on use of oral poliovirus vaccine (OPV) has identified suboptimal immunogenicity of this vaccine as a major impediment to eradication, with a failure to induce protection against paralytic poliomyelitis in certain population segments in some parts of the world. "
05/01/1984 - "Oral poliovirus vaccine administered during the first year of life has been effective in controlling poliomyelitis in tropical Africa."
10/01/1984 - "The present study showed that the neurovirulence test for the lesion-inducing virus dose in the spinal cord in 50% of monkeys inoculated with oral polio-vaccine (Sabin) (LID50) reflected to a large extent safety and efficacy of the vaccine upon administration to children. "
01/01/1981 - "Field trial on the efficacy of oral Sabin vaccine versus Salk polio vaccine."
06/01/1998 - "Serological evidence showed that the echovirus 11' infection was unable to interfere with the efficacy of oral poliovirus vaccine (OPV), since seroconversion rates of primovaccinees did not differ significantly from those in the group seroconverted also to echovirus 11' during the vaccination campaign. "
01/26/2001 - "This report summaries the results of that study, which indicate that oral poliovirus vaccine (OPV)-derived poliovirus type 2 circulated in Egypt during the 1980s and early 1990s and caused widespread infection and paralytic disease. "
01/01/2015 - "A small number of individuals with B-cell-related primary immunodeficiency diseases (PIDs) may exhibit long-term (prolonged or chronic) excretion of immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) following infection with oral poliovirus vaccine (OPV). "
11/01/2014 - "Assuming that India maintains high vaccination intensity everywhere, we do not anticipate issues with outbreaks of circulating vaccine-derived poliovirus type 2 infection following globally coordinated cessation of type 2-containting oral poliovirus vaccine use. "
10/25/2014 - "Intestinal immunity induced by oral poliovirus vaccine (OPV) is imperfect and wanes with time, permitting transmission of infection by immunised children. "
|3.||Glioblastoma (Glioblastoma Multiforme)
09/01/2008 - "Oral poliovirus vaccine (OPV) is reported to be effective in treatment of recurrent herpes simplex (RHS). "
12/01/1985 - "[Treatment of recurrent herpes simplex in medical personnel in a dermatology clinic using the trivalent poliomyelitis vaccine (Sabin)]."
01/01/1974 - "Preliminary report on the treatment of recurrent herpes simplex with poliomyelitis vaccine (Sabin's)."
04/01/1990 - " Agenda include during UIP contact at 6-8 weeks: diphtheria (DPT), oral poliovirus vaccine (OPV), and tuberculosis (bacillus Calmette-Guerin or BCG) shots; health assessment; and teaching of breast feeding to primipara. "
01/01/1999 - "Almost all children (94.4%) were vaccinated with all three doses of diphtheria-tetanus (DT), oral poliovirus vaccine (OPV), and hepatitis B. "
10/01/1998 - "Oral tetravalent rotavirus vaccine can be successfully coadministered with oral poliovirus vaccine and a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine. "
01/01/1994 - "Coverage levels for the third dose of diphtheria and tetanus toxoids and for oral poliovirus vaccine, which are mandatory, exceeded 90% in all but one area. "
03/01/2000 - "In 1998, overall regional vaccination coverage was 86% for diphtheria-pertussis-tetanus, 89% for oral poliovirus vaccine 3, 98% for bacille Calmette-Guérin vaccine, and 85% for measles. "
|1.||Inactivated Poliovirus Vaccine (Salk Vaccine)
|3.||Oral Poliovirus Vaccine (Sabin Vaccine)
|4.||Tetanus Toxoid (Vaccine, Tetanus)
|5.||Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (ActHIB)
|4.||Drug Therapy (Chemotherapy)